e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Guidelines and exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<%
A. Saleh, J. Lopez-Campos, S. Hartl, F. Pozo-Rodriguez, M. Roberts (London, United Kingdom; Seville, Madrid, Spain; Vienna, Austria)
Source:
Annual Congress 2013 –Guidelines and exacerbations
Session:
Guidelines and exacerbations
Session type:
Oral Presentation
Number:
176
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Saleh, J. Lopez-Campos, S. Hartl, F. Pozo-Rodriguez, M. Roberts (London, United Kingdom; Seville, Madrid, Spain; Vienna, Austria). Pneumonia risk in COPD patients on long term inhaled corticosteroids – Data from the European COPD audit<%. Eur Respir J 2013; 42: Suppl. 57, 176
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Survival in COPD patients with hospitalization due to exacerbation
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014
Screening eosinophil counts and risk of exacerbations after inhaled corticosteroid withdrawal in severe COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Impact of frequent exacerbations in patients with COPD
Source: International Congress 2014 – Clinical presentations
Year: 2014
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
COPD exacerbations occur more frequently in women – Data from the Bergmannsheil cohort
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Impact of bronchiectasis on duration of hospitalization in patients with exacerbations of COPD
Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations
Year: 2015
Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
Risk factors for another hospitalization in COPD patients hospitalized for exacerbation
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Recording and response to hyperglycaemia in patients presenting with infective exacerbations of COPD
Source: Annual Congress 2013 –Difficult and rare respiratory infections
Year: 2013
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
COPD and pneumonia
Source: International Congress 2015 – Different data in COPD
Year: 2015
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Mukoregulatory drugs in treating COPD
Source: International Congress 2014 – Predictors
Year: 2014
Characterising patterns of prescribing for UK COPD patients with comorbidities or history of pneumonia
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Vitamin D, exacerbations and hospitalizations in COPD patients
Source: Annual Congress 2013 –COPD diagnosis
Year: 2013
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Eosinophilia as marker of outcome in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD and infections
Year: 2013
Exacerbations and healthcare resource utilization among COPD patients in Sweden
Source: International Congress 2014 – Non inflammatory monitoring of airway diseases
Year: 2014
Cardiovascular medications and mortality in patients hospitalised with acute exacerbations of COPD
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept